

ASX Announcement | 18 November 2020 Althea Group Holdings (ASX:AGH)

Investor Webinar on Peak's fast start & Readying for Germany

18 November 2020: Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company') is pleased to invite shareholders and investors to a briefing with CEO Joshua Fegan to discuss announcements released to the ASX this week by the Company related to Peak Processing Solutions and the approval of Althea products for sale and distribution in Germany.

Details of the event are as follows:

Event: Althea Group Holdings Investor Briefing Presenters: CEO, Joshua Fegan Time: Thursday 19th November 2020, 11am (AEDT) Where: Zoom Webinar, details to be provided upon registration

To register your interest for the webinar, please click through to the link below: <u>https://us02web.zoom.us/webinar/register/WN_LaWV2YI4TX-QIKnalyOjeQ</u>

Participants will be able to submit questions via the chat function throughout the webinar, however, given we are expecting a large number of attendees we encourage shareholders to send through questions via email beforehand to the Company via Investor and Media Relations manager Jane Morgan at <u>im@janemorganmanagement.com.au</u>

Discussion points:

- Peak entering into a License Agreement with Canadian-based, Earth Kisses Sky, to produce two customer branded topical products, with 150,000 units (75,000 of each) expected to be purchased in year one
- Peak signing a Manufacturing and Distribution Services Agreement with Canadian cannabis beverage start-up, Electric Brands, to produce two canned beverage SKUs with an initial order of 50,000 units anticipated
- Germany's health department (BfArM) has now granted all necessary licenses for the sale and distribution of Althea products in Germany
- An initial order of 2,000 Althea products is expected to be delivered to German distribution partner Nimbus Health GmbH in December 2020
- Althea will become the first commercial supplier of Australian made medicinal cannabis extract products sold and distributed in the German market to date

-ENDS-

Authorised by: Robert Meissner, Company Secretary

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.lifeP. 1300 70 20 20W. althea.life

(O) @altheacompany



For further information, please contact:

Althea Josh Fegan CEO & Managing Director M: 1300 70 20 20 E: <u>contact@althea.life</u> Media Enquiries Dan Francome Media Relations P: +613 9650 5096 E: dfrancome@althea.life Investor Relations Jane Morgan Investor Relations Partner M: +61 405 555 618 E: jm@janemorganmanagement.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of products, education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into Germany, emerging markets throughout Asia and other parts of Europe.

To learn more, please visit: www.althea.life

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.lifeP. 1300 70 20 20W. althea.life